BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 33618135)

  • 1. Development and clinical validation of a simple and fast UPLC-ESI-MS/MS method for simultaneous quantification of nine kinase inhibitors and two antiandrogen drugs in human plasma: Interest for their therapeutic drug monitoring.
    Llopis B; Robidou P; Tissot N; Pinna B; Gougis P; Aubart FC; Campedel L; Abbar B; Weil DR; Uzunov M; Gligorov J; Salem JE; Funck-Brentano C; Zahr N
    J Pharm Biomed Anal; 2021 Apr; 197():113968. PubMed ID: 33618135
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring.
    Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L
    J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simple and accurate quantitative analysis of cefiderocol and ceftobiprole in human plasma using liquid chromatography-isotope dilution tandem mass spectrometry: interest for their therapeutic drug monitoring and pharmacokinetic studies.
    Llopis B; Bleibtreu A; Schlemmer D; Robidou P; Paccoud O; Tissot N; Noé G; Junot H; Luyt CÉ; Funck-Brentano C; Zahr N
    Clin Chem Lab Med; 2021 Oct; 59(11):1800-1810. PubMed ID: 34243226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS.
    Huynh HH; Pressiat C; Sauvageon H; Madelaine I; Maslanka P; Lebbé C; Thieblemont C; Goldwirt L; Mourah S
    Ther Drug Monit; 2017 Feb; 39(1):43-54. PubMed ID: 27861317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of an UPLC-MS/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring.
    Li G; Zhao M; Zhao L
    J Pharm Biomed Anal; 2022 Apr; 212():114517. PubMed ID: 35131665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel high-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification of BCR-ABL and Bruton's tyrosine kinase inhibitors and their three active metabolites in human plasma.
    Mukai Y; Yoshida T; Kondo T; Inotsume N; Toda T
    J Chromatogr B Analyt Technol Biomed Life Sci; 2020 Jan; 1137():121928. PubMed ID: 31877431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective quantification of 11 tyrosine kinase inhibitors and caffeine in human plasma by validated LC-MS/MS method with potent phospholipids clean-up procedure. Application to therapeutic drug monitoring.
    Koller D; Vaitsekhovich V; Mba C; Steegmann JL; Zubiaur P; Abad-Santos F; Wojnicz A
    Talanta; 2020 Feb; 208():120450. PubMed ID: 31816725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
    Lankheet NA; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH; Huitema AD
    Biomed Chromatogr; 2013 Apr; 27(4):466-76. PubMed ID: 22987603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma.
    Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O
    Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of cobimetinib, cabozantinib, dabrafenib, niraparib, olaparib, vemurafenib, regorafenib and its metabolite regorafenib M2 in human plasma by UPLC-MS/MS.
    Krens SD; van der Meulen E; Jansman FGA; Burger DM; van Erp NP
    Biomed Chromatogr; 2020 Mar; 34(3):e4758. PubMed ID: 31758580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An UPLC-MS/MS method for the quantification of BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (cobimetinib, trametinib, binimetinib) in human plasma. Application to treated melanoma patients.
    Rousset M; Titier K; Bouchet S; Dutriaux C; Pham-Ledard A; Prey S; Canal-Raffin M; Molimard M
    Clin Chim Acta; 2017 Jul; 470():8-13. PubMed ID: 28412197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and Validation of an LC-MS/MS Method for the Simultaneous Quantification of Abiraterone, Enzalutamide, and Their Major Metabolites in Human Plasma.
    van Nuland M; Hillebrand MJX; Rosing H; Schellens JHM; Beijnen JH
    Ther Drug Monit; 2017 Jun; 39(3):243-251. PubMed ID: 28490047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry.
    Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH
    Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A LC-MS/MS method for therapeutic drug monitoring of sorafenib, regorafenib and their active metabolites in patients with hepatocellular carcinoma.
    Iacuzzi V; Zanchetta M; Gagno S; Poetto AS; Orleni M; Marangon E; Guardascione M; Foltran L; Posocco B; Toffoli G
    J Pharm Biomed Anal; 2020 Aug; 187():113358. PubMed ID: 32460216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
    Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
    Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS.
    Bouchet S; Chauzit E; Ducint D; Castaing N; Canal-Raffin M; Moore N; Titier K; Molimard M
    Clin Chim Acta; 2011 May; 412(11-12):1060-7. PubMed ID: 21345336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous quantification and pharmacokinetic investigation of selexipag and its main metabolite ACT-333679 in rat plasma by UPLC-MS/MS method.
    Xie S; Shi L; Chen J; Xu RA; Ye X
    J Pharm Biomed Anal; 2020 Oct; 190():113496. PubMed ID: 32768890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel approach for the simultaneous quantification of 18 small molecule kinase inhibitors in human plasma: A platform for optimised KI dosing.
    van Dyk M; Miners JO; Kichenadasse G; McKinnon RA; Rowland A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1033-1034():17-26. PubMed ID: 27521531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous measurement of imatinib, nilotinib and dasatinib in dried blood spot by ultra high performance liquid chromatography tandem mass spectrometry.
    Kralj E; Trontelj J; Pajič T; Kristl A
    J Chromatogr B Analyt Technol Biomed Life Sci; 2012 Aug; 903():150-6. PubMed ID: 22857863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.